Clinical Trial Detail

NCT ID NCT02898259
Title Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

B-cell lymphoma

Therapies

Ixazomib + Lenalidomide + Rituximab

Age Groups: adult senior

No variant requirements are available.